Traditionally, clinical genetics services offered ‘reactive’ testing of specific cancer susceptibility genes (CSGs) to those with the corresponding classical presentation. Increasingly, cancer ...

One year ago, the PHG Foundation report, Host genomics: lessons for infectious diseases, highlighted the promise of host ...

The optimism is not unfounded. In specific, well-defined clinical scenarios, polygenic scores are beginning to demonstrate some tangible utility. For cardiovascular disease, MI-GENES, a 10-year follow ...

A patient arriving in A&E or another clinical setting, with suspected or known infection and the risk of sepsis, requires immediate action. Antibiotic admission more than one hour after suspected ...

The sepsis definition describes three elements: infection, the host response and life-threatening organ dysfunction. Diagnosis is made based on myriad signs and symptoms, and although infection ...

Sepsis is a critical global healthcare challenge, marked by complex and rapidly evolving symptoms, which can escalate with alarming speed leading to multi-organ failure. This leaves only a narrow ...

The term ‘mainstreaming’ was first used in 2003 by the Secretary of State for Health in the context of the genetics white paper Our Inheritance, Our Future when he argued that genomics must move from ...

Cost-utility studies provide critical information for the costs and benefits of using any new test, typically building on existing public health and screening programmes, within a defined population.

The Wellcome Trust recently announced that they are funding a research programme to investigate synthetic human genomes, and Laura Blackburn, PHG Foundation’s Head of Science, had the opportunity to ...

CAR-T is a powerful tool which is still evolving. Here we highlight what is new in CAR-T cell therapy Cancer cells often play hide-and-seek with the immune system in an attempt to evade catastrophic ...

In a world first, the NHS has announced it is rolling out ‘blood-test first’ testing for patients with non-small cell lung cancer (NSCLC) in England. The tests have been added to the Genomic Test ...